Thromboembolism and Major Bleeding in Patients with Atrial Fibrillation and EHRA Type 2 Valvular Heart Disease: The Jordan Atrial Fibrillation (JoFib) Study.
Mahasen Al-NajarMohammed Al-NusairNasr AlrabadiIbrahim AlawaishehTuqa AlawaishehMohamad Ismail JarrahKarem H AlzoubiSumaya NjemAyman J HammoudehPublished in: Vascular health and risk management (2023)
AF patients with EHRA type 2 VHD are at significant risk of thromboembolism and major bleeding. Furthermore, NOACs were more effective than VKAs in preventing thromboembolic events in this group of patients without conferring an added risk of major bleeding. Moreover, rivaroxaban appears to be particularly efficacious.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- direct oral anticoagulants
- end stage renal disease
- heart failure
- newly diagnosed
- ejection fraction
- percutaneous coronary intervention
- chronic kidney disease
- prognostic factors
- pulmonary embolism
- venous thromboembolism
- patient reported outcomes
- patient reported
- acute coronary syndrome
- aortic valve